Treatment of unstable angina with trimetazidine

( views:, downloads: )
Xiexing Chen(Cardiology Department 1 Affiliated Union Hospital 1 Fujian Medical University, Fuzhou 350001, China)
Mingfang Ye(Cardiology Department 1 Affiliated Union Hospital 1 Fujian Medical University, Fuzhou 350001, China)
Journal Title:
Volume 6, Issue 02, 2009
Key Word:
Coronary heart disease;trimetazidine;angina;unstable

Abstract: Objective To evaluate the clinical therapeutic effects oftrimetazidine on the treatment of unstable angina (UA) as well as its effects on endothelin-I level and complications of patients. Methods One hundred and twenty patients with UA were randomized into the trimetazidine group (n =60) and the control group (n =60), the trimetazidine group was subjected to treatment with 60 mg trimetazidine everyday for six months plus conventional treatment, and the clinical symptoms, changes in electrocardiogram, changes in the number of plasma circulating endothelial cells (CEC) and endothelin-1 level of the two groups were observed after treatment for four weeks; and the incidence rates of cardiac arrhythmias, cardiac failure, hospitalization due to angina, myocardial infarction and sudden death were also observed after treatment for six months. Results 1) The total effective rate of integrative clinical therapeutic effects in the trimetazidine group and the control group after treatment for four weeks were 86.7% and 68.3%,respectively (P<0.05), and the excellence rates were 36.7% and 15% (P<0.01)respectively; the total effective rates for the therapeutic effects in electrocardiogram were 66.7% and 46.7%,respectively (P<0.05), and the excellence rates were 30.0% and 11.7%, respectively (P<0.01 ). 2) The number of plasma CEC and endothelin-1 level of the two groups after treatment for four weeks significantly decreased (P<0.05), but the decreases in the trimetazidine group were even significant (P<0.01). 3) The incidence rates for cardiac arrhythmia in the trimetazidine group and the control group after treatment for six months were 10% and 20% (P<0.05), respectively, and the incidence rates for cardiac failure were 8.3% and 18.3%, respectively (P<0.05), and the incidence rates for hospitalization due to angina were 10% and 15%, and the incident rates for myocardial infarction were 3.3% and 13.3% respectively (P<0.05). Conclusion Trimetazidine can significantly improve the symptoms of UA and myocardial ischemia, reduce the damages to blood vessel endothelium and complications, and improve the prognosis.

  • [1]Sbarbati R,de Boer M,MarziUi M,et al.Immunologic detection of endothelial cells in human whole blood.Blood 1991;77:764-9.
  • [2]Jackson G.Stable angina:drugs,angioplasty or surgery? Eur Heart J 1997; 18(SupplB):B2-B10.
  • [3]Szwed H,Sadowski Z,Pachocki R,et al.Anti-ischaemie efficacy and tolerability of trimetazidine in elderly patients with angina pectoris.Clin Drug Invest 2001; 19:1-8.
  • [4]Szwed H,Sadowski Z,Elikowski W,et ai.Combination treatment in stable effort angina using trimetazidine and metoprolol:results of a randomized,double-blind,multicentre study (TRIMPOL Ⅱ).TRIMetazidine in POLand.Eur Heart J 2001; 22:2267-74.
  • [5]Cooperative group of multicentre clinical investigation on trimetazidine of China.The observations on the therapeutic effects of trimetazidine on stable angina pectoris of effort.Chinese Journal of Cardiology.2000; 28:339-41 (In Chinese).
  • [6]Kantor PF,Dyck JRB,Lopaschuk GD.Fatty acid oxidation in the reperfused ischemic heart.Am J Med Sci 1999; 318:3-14.
  • [7]Lopaschuk GD.Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.Presses Med 1998; 27:2100-4.
  • [8]Mody FV,Singh BN,Mohiuddin IH,et al.Trimetazidineinduced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue:an evaluation by positron emission tomography.Am J Cardiol 1998; 82:42-9K.
  • [9]El-Kady T,EI-Sabban K,Gabaly M,et al.Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemie cardiomyopathy:a 24-month study.Am J Cardiovase Drugs 2005; 5:271-8.
  • [10]Vasa M,Fichtlscherer S,Aicher A,et al.Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.Circ Res 2001; 89:E1-7.
  • [11]Vapaatalo H,Mervaala E.Clinically important factors influencing endothelial function.Med Sci Monit 2001; 7:1075-85.
  • [12]Li XY.Molecular biology of cardiovascular diseases.Beijing,The People's Military Medical Press,2000:226-229.(In Chinese).
  • [13]Monti LD,Allibardi S,Piatti PM,et al.Triglycerides impair postischemic recovery in isolated hearts:roles of endothelial1 and trimetazidine.Am J Physiol 2001; 281:H1122-30.
  • [14]Chen SS,Chen HQ,Wang W.Clinical observations of Vasorel in improving some functions of endothelial cells in patients that suffer from coronary heart disease.South Chin J Cardiovasc Disc 2004; 10:262-3.(In Chinese).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615